Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deanna L Kelly

Showing results (1-10 of 210) with videos related to

Pageof 21
Sort By:
Journal of Women'S Health (2002)|January 4, 2007
Treatment considerations in women with schizophreniaDeanna L Kelly
The Journal of Clinical Psychiatry|January 27, 2005
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazineDeanna L Kelly, Robert R Conley
Schizophrenia Research|January 24, 2022
Can the current schizophrenia construct endure?Deanna L Kelly, Robert W Buchanan
Psychopharmacology Bulletin|February 8, 2007
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patientsRobert R Conley, Deanna L Kelly
The Israel Journal of Psychiatry and Related Sciences|September 2, 2005
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effectsRobert R Conley, Deanna L Kelly
Schizophrenia Research|August 2, 2003
Evaluating sexual function in patients with treatment-resistant schizophreniaDeanna L Kelly, Robert R Conley
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 15, 2003
Olanzapine and risperidoneRaymond C Love, Deanna L Kelly
The Mental Health Clinician|March 8, 2019
Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving managementDeanna L Kelly, Raymond C Love
Schizophrenia Bulletin|June 15, 2005
Sexuality and schizophrenia: a reviewDeanna L Kelly, Robert R Conley
Psychoneuroendocrinology|October 4, 2005
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophreniaDeanna L Kelly, Robert R Conley
Pageof 21

Showing results (1-10 of 210) with videos related to

Sort By:
Pageof 21
Journal of Women'S Health (2002)|January 4, 2007
Treatment considerations in women with schizophreniaDeanna L Kelly
The Journal of Clinical Psychiatry|January 27, 2005
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazineDeanna L Kelly, Robert R Conley
Schizophrenia Research|January 24, 2022
Can the current schizophrenia construct endure?Deanna L Kelly, Robert W Buchanan
Psychopharmacology Bulletin|February 8, 2007
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patientsRobert R Conley, Deanna L Kelly
The Israel Journal of Psychiatry and Related Sciences|September 2, 2005
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effectsRobert R Conley, Deanna L Kelly
Schizophrenia Research|August 2, 2003
Evaluating sexual function in patients with treatment-resistant schizophreniaDeanna L Kelly, Robert R Conley
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 15, 2003
Olanzapine and risperidoneRaymond C Love, Deanna L Kelly
The Mental Health Clinician|March 8, 2019
Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving managementDeanna L Kelly, Raymond C Love
Schizophrenia Bulletin|June 15, 2005
Sexuality and schizophrenia: a reviewDeanna L Kelly, Robert R Conley
Psychoneuroendocrinology|October 4, 2005
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophreniaDeanna L Kelly, Robert R Conley
Pageof 21